Polygenic risk of idiopathic pulmonary fibrosis and COVID-19 severity
Abstract Introduction Coronavirus disease 2019 (COVID-19) survivors can develop residual lung abnormalities consistent with lung fibrosis. A shared genetic component between COVID-19 and idiopathic pulmonary fibrosis (IPF) has been shown. However, genetic overlap studies of IPF and COVID-19 have primarily concentrated on the IPF genome-wide significant risk variants that have been previously identified, rather than combined into a genome-wide polygenic risk. Here we used IPF genome-wide association study (GWAS) results to calculate polygenic risk scores (PRSs) and study their association with COVID-19 severity.Methods We used results from the largest meta-GWAS of clinically defined IPF risk (base dataset; n=24,589) and individual-level imputed data from the SCOURGE study of patients with COVID-19 (target dataset; n=15,024). We calculated IPF PRSs using PRSice-2 and assessed their association with COVID-19 hospitalisation, severe illness, and critical illness. We also evaluated the effect of age and sex stratification. Results were validated using an independent PRS method. Enrichment analyses and pathway-specific PRSs were performed to study biological pathways associated with COVID-19 severity.Results IPF PRSs were significantly associated with COVID-19 hospitalisation and severe illness. The strongest association was found in patients aged <60 years, especially among younger males (OR=1.16; 95%CI=1.08-1.25; p=6.39×10−5). A pathway enrichment analysis of the variants included in the best model fit and subsequent pathway-specific PRSs analyses supported the link of Cadherin and Integrin signalling pathways to COVID-19 severity when stratified by age and sex.Conclusion Our results suggest that there is genome-wide genetic overlap between IPF and severe COVID-19 that is dependent on age and sex and adds further support that the pathogenesis of both IPF and severe COVID-19 share underlying biological mechanisms. This could imply that individuals with a high IPF genetic risk are at an overall increased risk of developing lung sequelae resulting from severe COVID-19..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
bioRxiv.org - (2023) vom: 16. Juni Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Guillen-Guio, Beatriz [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
---|
doi: |
10.1101/2023.06.12.23291269 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XBI039891208 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XBI039891208 | ||
003 | DE-627 | ||
005 | 20231205144903.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230614s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2023.06.12.23291269 |2 doi | |
035 | |a (DE-627)XBI039891208 | ||
035 | |a (biorXiv)10.1101/2023.06.12.23291269 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Guillen-Guio, Beatriz |e verfasserin |0 (orcid)0000-0002-3703-1738 |4 aut | |
245 | 1 | 0 | |a Polygenic risk of idiopathic pulmonary fibrosis and COVID-19 severity |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Introduction Coronavirus disease 2019 (COVID-19) survivors can develop residual lung abnormalities consistent with lung fibrosis. A shared genetic component between COVID-19 and idiopathic pulmonary fibrosis (IPF) has been shown. However, genetic overlap studies of IPF and COVID-19 have primarily concentrated on the IPF genome-wide significant risk variants that have been previously identified, rather than combined into a genome-wide polygenic risk. Here we used IPF genome-wide association study (GWAS) results to calculate polygenic risk scores (PRSs) and study their association with COVID-19 severity.Methods We used results from the largest meta-GWAS of clinically defined IPF risk (base dataset; n=24,589) and individual-level imputed data from the SCOURGE study of patients with COVID-19 (target dataset; n=15,024). We calculated IPF PRSs using PRSice-2 and assessed their association with COVID-19 hospitalisation, severe illness, and critical illness. We also evaluated the effect of age and sex stratification. Results were validated using an independent PRS method. Enrichment analyses and pathway-specific PRSs were performed to study biological pathways associated with COVID-19 severity.Results IPF PRSs were significantly associated with COVID-19 hospitalisation and severe illness. The strongest association was found in patients aged <60 years, especially among younger males (OR=1.16; 95%CI=1.08-1.25; p=6.39×10−5). A pathway enrichment analysis of the variants included in the best model fit and subsequent pathway-specific PRSs analyses supported the link of Cadherin and Integrin signalling pathways to COVID-19 severity when stratified by age and sex.Conclusion Our results suggest that there is genome-wide genetic overlap between IPF and severe COVID-19 that is dependent on age and sex and adds further support that the pathogenesis of both IPF and severe COVID-19 share underlying biological mechanisms. This could imply that individuals with a high IPF genetic risk are at an overall increased risk of developing lung sequelae resulting from severe COVID-19. | ||
650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
700 | 1 | |a Marcelino-Rodriguez, Itahisa |0 (orcid)0000-0003-3645-3207 |4 aut | |
700 | 1 | |a Lorenzo-Salazar, Jose Miguel |4 aut | |
700 | 1 | |a Leavy, Olivia C |0 (orcid)0000-0002-1503-5535 |4 aut | |
700 | 1 | |a Allen, Richard J |0 (orcid)0000-0002-8450-3056 |4 aut | |
700 | 1 | |a Riancho, José A. |0 (orcid)0000-0003-0691-8755 |4 aut | |
700 | 1 | |a Rojas, Augusto |0 (orcid)0000-0003-3765-6778 |4 aut | |
700 | 1 | |a Lapunzina, Pablo |0 (orcid)0000-0002-6324-4825 |4 aut | |
700 | 1 | |a Carracedo, Ángel |0 (orcid)0000-0003-1085-8986 |4 aut | |
700 | 1 | |a Wain, Louise V |0 (orcid)0000-0003-4951-1867 |4 aut | |
700 | 1 | |a Flores, Carlos |0 (orcid)0000-0001-5352-069X |4 aut | |
773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 16. Juni |
773 | 1 | 8 | |g year:2023 |g day:16 |g month:06 |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.06.12.23291269 |z kostenfrei |3 Volltext |
912 | |a GBV_XBI | ||
951 | |a AR | ||
952 | |j 2023 |b 16 |c 06 |